AGN Media thread, page-105

Firstly AGN is yet to be approved for nothing by the FDA and many drugs still fail well into phase 3 so having a possible better efficacy we won’t know until one of the drugs get approved by the FDA. For now there is no treatment for a potential 100 billion dollar plus injury and that is why the upside for both in share price is exponential

Secondly NYR is not 3 years behind. AGN has 1.5 years before it completes phase 2 due to a slow uptake having done phase 2 in Australia. NYR which starts phase 2 end next year in America will have a faster uptake that you would expect phase 2 to complete within 8-12 months. So your only 12 months ahead

Thirdly AGN has only completed phase 1 and started phase 2 for stroke victims. NYR is about to begin phase 1 for both Stroke and traumatic brain injury. NYR will be the only drug in the world that will be approved for both traumatic brain injury and stroke. AGN will need to start phase 1 again for traumatic brain injury. So even if AGN does come in market it needs another 8 years for traumatic brain injury approval. AGN will be 8 years behind NYR unless they invest additional funding and increase heavily their dilution of the company into traumatic brain injury which they don’t have the funds for and need it for stroke.

Both drugs will revolutionise the industry and I own both. But NYR will make it to market for both conditions before AGN will ever do